- Company
- Sales of the flu tx market increased due to the endemic
- by Chon, Seung-Hyun Aug 7, 2023 05:23am
- In the first half of the year, the outpatient prescription market for flu treatment exceeded 10 billion won in four years. As the number of flu patients surged after the end of the Corona 19 pandemic, the flu treatment market, which had disappeared over the past three years, expanded significantly. According to UBIST, a drug research institut
- Company
- Prescription of HA eye drops record KRW 166 bil in 1H
- by Kim, Jin-Gu Aug 7, 2023 05:23am
- The prescription market for hyaluronic acid eye drops grew to record the largest scale ever ahead of the reimbursement reevaluations set for the end of this year. In 1H alone, the market grew exceeded KRW 160 billion in prescriptions this year. The number of companies with half-year prescriptions that exceed KRW 10 billion increased fro
- Company
- Prescriptions of pseudoephedrine rise 35% in 1H
- by Chon, Seung-Hyun Aug 4, 2023 05:38am
- The prescription market for ‘pseudoephedrine,’ which continues to show an unstable supply and demand in the market, has expanded significantly. Despite the end of the pandemic, demand for the drug has increased significantly due to the increase in flu and cold patients. Accordingly, the need to raise the insurance price ceiling for the low-pri
- Company
- Antibiotic resistance is serious
- by Jung, Sae-Im Aug 4, 2023 05:37am
- Antibiotic resistance has been a global issue for several years. In 2016, the British government predicted that 700,000 people worldwide would die from antibiotic-resistant bacteria every year and that the death toll would reach 10 million by 2050 if no special measures were taken. In 2015, the World Health Organization (WHO) presented a 'global
- Company
- Variable for contract renewal for joint sales
- by Kim, Jin-Gu Aug 3, 2023 05:35am
- HK inno.N r, up 17% in about a year after the launch. HK inno.N sold alone, no commission share, profitability improved as more sold Expiration of the joint sales contract with Chong Kun Dang at the end of the year, will it affect renewal negotiations? HK inno.N K-Cab OD tablets accounted for 17.0% of the total prescription performanc
- Company
- Rise of 4-drug combos in hypertension/hyperlipidemia Tx mkt
- by Kim, Jin-Gu Aug 3, 2023 05:35am
- The growth of 3-drug combinations has slowed down in the hypertension/hyperlipidemia combination drug market. After recording double-digit YoY growth every quarter until the first half of last year, the spurt has slowed sharply since the end of last year. On the other hand, the 4-drug combinations that newly entered the market are rapidly exp
- Company
- Rx of Generics for Xarelto doubled in 1 yr
- by Kim, Jin-Gu Aug 2, 2023 05:25am
- Generics for Xarelto (Rivaroxaban) are rapidly increasing their prescription performance. In the first half of last year, prescription sales of 8 billion won were recorded, more than doubling in one year. On the other hand, the original product's prescription performance decreased by half during the same period. Generics for Xarelto, 3.9 b
- Company
- Why HK Inno.N’s sales and operating profit fell
- by Kim, Jin-Gu Aug 2, 2023 05:25am
- HK Inno.N's sales and operating profit declined significantly in Q2 this year. This can be attributed to the sharp decline in MSD vaccine sales amid brisk earnings of its flagship product, K-Cab (tegoprazan),. HK InnoN explained that shipments of Gardasil, its cervical cancer vaccine, were concentrated in the second quarter of last year b
- Company
- GC Biopharma ends its 2-quarter deficit run
- by Kim, Jin-Gu Aug 2, 2023 05:25am
- GC Biopharma, which had recorded an operating loss for 2 consecutive quarters, succeeded in turning a profit this quarter. GC Biopharma explained that the company has succeeded in doing so by increasing sales of highly profitable products and efficient execution of costs. GC Biopharma also announced plans to accelerate its overseas busine
- Company
- Inrebic, tx for myelofibrosis, has become available in Big5
- by Eo, Yun-Ho Aug 2, 2023 05:25am
- Inrebic, a new drug for myelofibrosis, has settled down in Big 5. According to related industries, Korea BMS Pharmaceutical's myelofibrosis treatment Inrebic passed the Drug Committee (DC) of the big five medical institutions, including SMC, Seoul National University Hospital, Seoul St. Mary's Hospital, Asan Medical Center, and Severance Hos
